Centessa Pharmaceuticals Net Worth
Centessa Pharmaceuticals Net Worth Breakdown | CNTA |
Centessa Pharmaceuticals Net Worth Analysis
Centessa Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Centessa Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Centessa Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Centessa Pharmaceuticals' net worth analysis. One common approach is to calculate Centessa Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Centessa Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Centessa Pharmaceuticals' net worth. This approach calculates the present value of Centessa Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Centessa Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Centessa Pharmaceuticals' net worth. This involves comparing Centessa Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Centessa Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Centessa Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Centessa Pharmaceuticals' net worth research are outlined below:
| Centessa Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 6.85 M. Net Loss for the year was (151.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Centessa Pharmaceuticals PLC currently holds about 484.16 M in cash with (160.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.13. | |
| Centessa Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Centessa Pharmaceuticals Shares Down 4.5 percent Time to Sell |
Centessa Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Centessa Pharmaceuticals PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Centessa Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Centessa Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Centessa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Centessa Pharmaceuticals PLC backward and forwards among themselves. Centessa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Centessa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tcg Crossover Management, Llc | 2024-09-30 | 2.9 M | Farallon Capital Management, L.l.c. | 2024-09-30 | 2.8 M | Point72 Asset Management, L.p. | 2024-09-30 | 2.7 M | Cormorant Asset Management, Llc | 2024-09-30 | 2.6 M | Franklin Resources Inc | 2024-09-30 | 2.3 M | Avidity Partners Management Lp | 2024-09-30 | 2.1 M | Artal Group S A | 2024-06-30 | 2.1 M | Driehaus Capital Management Llc | 2024-06-30 | 2.1 M | Octagon Capital Advisors Lp | 2024-09-30 | 2 M | Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 20 M | General Atlantic Llc | 2024-09-30 | 9.7 M |
Follow Centessa Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.25 B.Market Cap |
|
Project Centessa Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.64) | (0.67) |
When accessing Centessa Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Centessa Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Centessa Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Centessa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Centessa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Centessa Pharmaceuticals' management manipulating its earnings.
Evaluate Centessa Pharmaceuticals' management efficiency
Centessa Pharmaceuticals has return on total asset (ROA) of (0.2047) % which means that it has lost $0.2047 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4252) %, meaning that it created substantial loss on money invested by shareholders. Centessa Pharmaceuticals' management efficiency ratios could be used to measure how well Centessa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.56. At present, Centessa Pharmaceuticals' Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.26, whereas Total Assets are forecasted to decline to about 322.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.46 | 2.27 | |
| Tangible Book Value Per Share | 2.46 | 2.27 | |
| Enterprise Value Over EBITDA | (4.35) | (4.57) | |
| Price Book Value Ratio | 3.24 | 3.40 | |
| Enterprise Value Multiple | (4.35) | (4.57) | |
| Price Fair Value | 3.24 | 3.40 | |
| Enterprise Value | 722.1 M | 758.2 M |
Understanding the operational decisions made by Centessa Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 264.5437 | Revenue 6.9 M | Revenue Per Share 0.065 | Return On Equity (0.43) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Centessa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Centessa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Centessa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Centessa Pharmaceuticals Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 18th of October 2024 Other Reports | ViewVerify |
Centessa Pharmaceuticals Earnings per Share Projection vs Actual
Centessa Pharmaceuticals Corporate Management
| Tia Bush | Chief Officer | Profile | |
| Ellie MD | Senior Oncology | Profile | |
| MD MSc | Ex Devel | Profile | |
| April Dovholuk | Senior Operations | Profile | |
| JD Esq | Senior Communications | Profile | |
| MBA MD | Principal CFO | Profile | |
| David Chao | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.065 | Return On Assets (0.20) | Return On Equity (0.43) |
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.